Week 6 Respiratory and Gout Flashcards
(47 cards)
Asthma
Chronic inflammatory disorder of the airways
50% results from an immune response to an allergen
Allergen binds to IgE on mast cells
Mast cells release mediators (DRUGS TARGET THESE)
Mediators cause bronchoconstriction and airway inflammation
COPD
3rd leading cause of death
Irreversibel symptoms from:
Chronic bronchitis (chronic cough with excessive sputum production)
Emphysema– enlargement of airspace within the bronchioles/alveoli
Diagnoses: FEV1/FVC= <0.7 (70%)
Inflammation from mediators inhibits protease inhibitors who protect and maintain alveoli integrity; without them enzymes break down elastin
Anti Inflammatory
Glucocorticoids
Budesonide and Fluticasone
MOA: < release of inflammatory mediators (histamine, leukotrienes, and prostaglandins)
USE: Asthma prophylaxis and COPD exacerbation mangement
ADE: inhaled: oral thrush; long term adrenal suppression and bone loss
ORAL glucocorticoids can cause toxicity and should not be first line
PT ED: intended for prevention not acute attacks; rinse mouth post use
Anti Inflammatory
Leukotriene Receptor Antagonists
Zilueton; Zafirlukast (prototype)
Montelukast (TESTED ON) Only one approved for children 1-3
MOA: high affinity for leukotriene receptors in the airway on pro-inflammatory cells blocking receptor activation
Use: prophylactic and maintenance therapy for asthma; prevention of EIB exercise inducted bronchospasm
ADE: possible neuropsychiatric impact (mood/ suicide)
PT ED: Cannot be used for quick relief from an attack
Provider considerations: SABA preferred for EIB
Anti Inflammatory
Other Category (1 drug)
Cromolyn
Inhaled agent that suppresses bronchial inflammation
Use: Prophylaxis in mild to moderate asthma
Less effective than glucocorticoids; not preferred
Only prescribe is pt has an issue with glucocorticoids
SAFEST DRUG
Admin via nebulizer
Anti Inflammatory Life Stages
inhaled glucocorticoids are preferred tx for children, pregnant women, breastfeeding, and inhaled is safer than systemic in all categories for older adults
MABS Monoclonal Antibodies
OmalizuMAB
Tx asthma
MOA: forms complex with IgE reducing amount of IgE available to bind with mast cells limiting mediator release
Approved for ages 6 and ^ for allergy related asthma not controlled by glucocorticoids
Sub Q injection; half life 26 days
Once stopped, will take IgE 1 year to return to pretreatment levels
Phosphodieterase 4 Inhibitor
Roflumilast
MOA: target ^ cAMP to inhibit inflammation
Use: mange COPD w/ primary chronic bronchitis component; exacerbation prophylaxis
ADE: headache, insomnia, GI (N/V/D weight loss, reduced appetite)
Bronchodilators
Anticholinergic Drugs
IpraTROPIUM/ TioTROPIUM
IpraTROPIUM
SAMA
MOA: Blocks muscarinic receptors in bronchi reducing bronchoconstriction
USE: COPD approved
ADE: minimal dry mouth or irritation of pharynx
***PT ED: Risk for ^ interocular pressure; frequent eye exams with glaucoma
TioTROPIUM
Long acting muscarinic antagonist (LAMA)
Same use/ effects peak 3 hours; last 24 hours
Each dose more relief; plateau at 8 days
ADE: dry mouth; less common anticholinergic effects: can’t see, can’t pee; can’t spit, can’t shit)
Bronchodilators
Beta 2 Agonists SABA
Albuterol/ Xopenex/ Levalbuterol/ Proair/ Proventil
Use: 1st line acute asthma attacks; prophylaxis EIB
MOA: activates B2 receptors; smooth muscle in lung promotes bronchodilation
Dose: 1-2 breaths
Pt ED: cannot be used for prolonged prophylaxis, only for acute attack and EIB prophylaxis
PRN
Albuterol in Neonates: prevent BPD, relive brochospasm, TTN, viral bronchiolitis (all little research)
Intra-tracheal albuterol and surfactant; positive effect in reducing Intubation- Surfactant Extubations failure
Bronchodilators
Beta 2 Agonists LABA
Salmeterol/ Formoterol/ Arformoteral
MOA: activates B2 in lung
Use: longterm prophylaxis in pts with frequent asthma attacks; Preferred in COPD
PT ED: Take on a fixed schedule
BLACK BOX: Asthma related deaths from monotherapy
Bronchodilator
Unknown Mechanism
Methylxanthine
MOA: unknown
USE: maintenance therapy for asthma; nocturnal asthmatics; not for COPD
ADE: r/t toxicity; NV and tachy-dysrythmias
If toxic dose, stop dosage and consider charcoal
PT ED: Drug interactions: caffeine, tobacco, phenobarb, phenytoin, rifampin, and fluoroquinolone abx
Bronchodilator Life Stage
SABAs are for children >2
Methylxanthines for any age (neonates)
Preg: beta 2 agonists exceed risk of uterine relaxation and poor oxygen delivery to fetus
Anticholinergics are the safest
Breastfeeding: avoid methyxanthine
Older: systemic anticholinergics BEERS list
Methyxanthine risk of toxicity; avoid
Treatment Goals ASTHMA
Reduce impairment
Reduce Risk
Severity of illness:
Intermittent: Step 1
Mild persistent: Step 2
Moderate persistent: Step 3
Sever persistent: Step 4/5
Step 1: PRN SABA
Step 2: daily low dose ICS and PRN SABA/// OR/// PRN concomitant ICS and SABA
Step 3: Daily and PRN combo of low-dose ICS–Formoterol
Step 4: Daily and PRN combo medium dose–Formoterol
Step 5: Daily medium high dose ICS-LABA + LAMA and PRN SABA
Step 6: Daily high dose ICS-LABA +oral systemic corticosteroids and PRN SABA
Treatment Goals for COPD
Reduce Symptoms
Reduce Risk
Diagnosis: GOLD assessment
0-1 Moderate exacerbations not leading to hospitalization:
Group A: bronchodilator
Group B: long acting bronchodilator (LABA or LAMA)
> 2 moderate exacerbations or >1 leading to hospitalization:
Group C: LAMA
Group D: LAMA or LAMA + LABA or ICS + LABA
Allergic Rhinitis
Inflammatory disorder affecting upper airway
Sneezing, rhinorrhea, pruitis, nasal congestion
Main cause: Dilation and increased permeability of nasal blood vessels
Triggered: airborne allergens that bind to mask cells
Seasonal: hay fever, occurs in spring and fall, fungus, pollen, weed grass, trees
Perennial: Indoor allergens, pet dander, dust mites
Allergic Rhinitis
Drug Categories and Drugs
Inranasal Glucocorticoid: Beclomethasone
Antihistamine: Azelastine/Loratadine
Intranasal Sympathomimetics: Phenylephrine; oxymetazoline
Oral Sympathomimetics: Psuedoephendrine
Allergic Rhinitis
Glucocorticoids
Beclomethasone/ budesonide/ fluticasone propionate/ triamcinolone
prevent inflammatory response to allergies; reduce symptoms
ADE: nasal irritation, burning/ itching, sore throat, nose bleeds, headache
MOST EFFECTIVE
Metered dose spray
Admin daily
Allergic Rhinitis
Antihistamines
Azelastine/ Olopatadine
H1 receptor antagonist
first line for mild to moderate rhinitis
more effective taken prophylactically
Relieves sneezing and nasal itching but not congestion
ADE: sedation, dry nose, dry mouth, constipation, urinary hesitancy
Sympathomimetics (Decongestants)
Psuedoephendrine
Activate A1 adrenergic receptors on nasal blood vessels
Only relieves congestion
ADE: Rebound congestion, CNS stimulation, CV impact, abuse
TX Allergic Rhinitis based on chief complain
Nasal Decongestion: glucocorticoids and oral decongestant
Intermittent sneezing and rhinorrhea: oral and internasal antihistamine
Mild symptoms: oral antihistamine
Moderate to severe: nasal glucocorticoids. intranasal antihistamines, and combo therapy
Cough
Not all cough is useful
irritation of bronchial mucosa reflex
Opiod antitussive, non opioid antitussive, expectorants, mucolytics
Cough opioid antissive
Codeine, hydrocodeine
Suppress cough
1/10 of the dose for pain (10-20mg PO)
Not recommended in kids
Cough Non opioid antissive
Dextromethorphan
Acts in CNS
Can cause euphoria
10-30mg Q 4-8 hours
Diphenhydramine
Antihistamine
mechanism to suppress cough is unclear
Can cause Sedation
Benzonatate Decreases cough by decreasing sensitivity of respiratory tract stretch receptors
Avoid in children < 10
adopt dose 100mg TID